Masaki Miyazaki

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial

Haruhiro Saito, Tatsuro Fukuhara, Naoki Furuya et al. · The Lancet Oncology · 2019 · 626 citations

Interim Analysis, Oncology, Bevacizumab Versus Erlotinib +8

Phase III Trial Comparing Oral S-1 Plus Carboplatin With Paclitaxel Plus Carboplatin in Chemotherapy-Naïve Patients With Advanced Non–Small-Cell Lung Cancer: Results of a West Japan Oncology Group Study

Isamu Okamoto, Hiroshige Yoshioka, Satoshi Morita et al. · Journal of Clinical Oncology · 2010 · 163 citations

Analysis of comorbid factors that increase the COPD assessment test scores

Masaki Miyazaki, Hidetoshi Nakamura, Shotaro Chubachi et al. · Respiratory Research · 2014 · 101 citations · Full text

Phase I Clinical and Pharmacokinetic Study of RAD001 (Everolimus) Administered Daily to Japanese Patients with Advanced Solid Tumors

Isamu Okamoto, Toshihiko Doi, Atsushi Ohtsu et al. · Japanese Journal of Clinical Oncology · 2009 · 74 citations · Full text

Severe Acute Interstitial Lung Disease After Crizotinib Therapy in a Patient With <i>EML4-ALK</i>–Positive Non–Small-Cell Lung Cancer

Akihiro Tamiya, Isamu Okamoto, Masaki Miyazaki et al. · Journal of Clinical Oncology · 2012 · 70 citations · Full text

Advanced Lung Disease, Medicine, Pulmonary Alveolar Proteinosis +7